What is ibandronate used for?

Indications and Usage, quoted from the label by Aurobindo Pharma Limited (ANDA204502). Cross-references to other label sections are left out.

Treatment and Prevention of Postmenopausal Osteoporosis

Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium tablets increase bone mineral density (BMD) and reduce the incidence of vertebral fractures.

Important Limitations of Use

The optimal duration of use has not been determined. The safety and effectiveness of ibandronate sodium tablets for the treatment of osteoporosis are based on clinical data of three years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

Source: DailyMed label, set id 86c0b4ae-5e38-4efe-88af-50ac560e294f, version 12, effective March 18, 2026. NDC 65862-237, one of 3 listings for this product.

Indications and Usage, quoted from the label by Bionpharma Inc. (ANDA078998). Cross-references to other label sections are left out.

Treatment and Prevention of Postmenopausal Osteoporosis

Ibandronate Sodium Tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. Ibandronate sodium increases bone mineral density (BMD) and reduces the incidence of vertebral fractures.

Important Limitations of Use

The optimal duration of use has not been determined. The safety and effectiveness of Ibandronate Sodium Tablets for the treatment of osteoporosis are based on clinical data of three years duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

Source: DailyMed label, set id 6ca94cce-a2bb-421f-bd8f-6b14bc2bd985, version 6, effective August 26, 2026. NDC 69452-378, one of 3 listings for this product.

Indications and Usage, quoted from the label by Sun Pharmaceutical Industries, Inc. (ANDA090853). Cross-references to other label sections are left out.

Treatment of Postmenopausal Osteoporosis

Ibandronate sodium injection is indicated for the treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, ibandronate sodium injection increases bone mineral density (BMD) and reduces the incidence of vertebral fractures.

Important Limitations of Use

The safety and effectiveness of ibandronate sodium injection for the treatment of osteoporosis are based on clinical data of one year duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture re-evaluated periodically.

Source: DailyMed label, set id be514be6-727a-4d6c-993b-52144f8e6de8, version 6, effective March 3, 2026. NDC 62756-218, one of 2 listings for this product.